372 related articles for article (PubMed ID: 20621252)
1. The genetics of vascular complications in diabetes mellitus.
Farbstein D; Levy AP
Cardiol Clin; 2010 Aug; 28(3):477-96. PubMed ID: 20621252
[TBL] [Abstract][Full Text] [Related]
2. Haptoglobin genotype and its role in diabetic cardiovascular disease.
Costacou T; Levy AP
J Cardiovasc Transl Res; 2012 Aug; 5(4):423-35. PubMed ID: 22447230
[TBL] [Abstract][Full Text] [Related]
3. Genetics of diabetic cardiovascular disease: identification of a major susceptibility gene.
Levy AP
Acta Diabetol; 2003 Dec; 40 Suppl 2():S330-3. PubMed ID: 14704863
[TBL] [Abstract][Full Text] [Related]
4. In vivo and in vitro studies establishing haptoglobin as a major susceptibility gene for diabetic vascular disease.
Asleh R; Levy AP
Vasc Health Risk Manag; 2005; 1(1):19-28. PubMed ID: 17319095
[TBL] [Abstract][Full Text] [Related]
5. The protean role of haptoglobin and haptoglobin genotypes on vascular complications in diabetes mellitus.
Dalan R; Liuh Ling G
Eur J Prev Cardiol; 2018 Sep; 25(14):1502-1519. PubMed ID: 29799294
[TBL] [Abstract][Full Text] [Related]
6. The Role of Haptoglobin Polymorphism in Cardiovascular Disease in the Setting of Diabetes.
Somer S; Levy AP
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396615
[TBL] [Abstract][Full Text] [Related]
7. Haptoglobin phenotype is an independent risk factor for cardiovascular disease in individuals with diabetes: The Strong Heart Study.
Levy AP; Hochberg I; Jablonski K; Resnick HE; Lee ET; Best L; Howard BV;
J Am Coll Cardiol; 2002 Dec; 40(11):1984-90. PubMed ID: 12475459
[TBL] [Abstract][Full Text] [Related]
8. Association of RAGE gene polymorphism with circulating AGEs level and paraoxonase activity in relation to macro-vascular complications in Indian type 2 diabetes mellitus patients.
Bansal S; Chawla D; Banerjee BD; Madhu SV; Tripathi AK
Gene; 2013 Sep; 526(2):325-30. PubMed ID: 23721855
[TBL] [Abstract][Full Text] [Related]
9. Association analysis of genes in the renin-angiotensin system with subclinical cardiovascular disease in families with Type 2 diabetes mellitus: the Diabetes Heart Study.
Burdon KP; Langefeld CD; Wagenknecht LE; Carr JJ; Freedman BI; Herrington D; Bowden DW
Diabet Med; 2006 Mar; 23(3):228-34. PubMed ID: 16492203
[TBL] [Abstract][Full Text] [Related]
10. The roles of endothelial nitric oxide synthase gene polymorphisms in diabetes mellitus and its associated vascular complications: a systematic review and meta-analysis.
Dong J; Ping Y; Wang Y; Zhang Y
Endocrine; 2018 Nov; 62(2):412-422. PubMed ID: 30140993
[TBL] [Abstract][Full Text] [Related]
11. Endothelial nitric oxide synthase polymorphisms are associated with type 2 diabetes and the insulin resistance syndrome.
Monti LD; Barlassina C; Citterio L; Galluccio E; Berzuini C; Setola E; Valsecchi G; Lucotti P; Pozza G; Bernardinelli L; Casari G; Piatti P
Diabetes; 2003 May; 52(5):1270-5. PubMed ID: 12716763
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomics in prevention of diabetic cardiovascular disease: utilization of the haptoglobin genotype in determining benefit from vitamin E.
Levy AP; Blum S
Expert Rev Cardiovasc Ther; 2007 Nov; 5(6):1105-11. PubMed ID: 18035926
[TBL] [Abstract][Full Text] [Related]
13. Cumulative effect of oxidative stress-related gene polymorphisms on myocardial infarction in type 2 diabetes.
Katakami N; Sakamoto K; Kaneto H; Matsuhisa M; Ohno K; Shimizu I; Ishibashi F; Osonoi T; Kashiwagi A; Kawamori R; Yamasaki Y
Diabetes Care; 2009 May; 32(5):e55. PubMed ID: 19407065
[No Abstract] [Full Text] [Related]
14. Macro- and microvascular endothelial dysfunction in diabetes.
Shi Y; Vanhoutte PM
J Diabetes; 2017 May; 9(5):434-449. PubMed ID: 28044409
[TBL] [Abstract][Full Text] [Related]
15. Lack of association between polymorphisms of catalase, copper-zinc superoxide dismutase (SOD), extracellular SOD and endothelial nitric oxide synthase genes and macroangiopathy in patients with type 2 diabetes mellitus.
Ukkola O; Erkkilä PH; Savolainen MJ; Kesäniemi YA
J Intern Med; 2001 May; 249(5):451-9. PubMed ID: 11350569
[TBL] [Abstract][Full Text] [Related]
16. Application of pharmacogenomics in the prevention of diabetic cardiovascular disease: mechanistic basis and clinical evidence for utilization of the haptoglobin genotype in determining benefit from antioxidant therapy.
Levy AP
Pharmacol Ther; 2006 Nov; 112(2):501-12. PubMed ID: 16854468
[TBL] [Abstract][Full Text] [Related]
17. Relationship of paraoxonase 1 (PON1) gene polymorphisms and functional activity with systemic oxidative stress and cardiovascular risk.
Bhattacharyya T; Nicholls SJ; Topol EJ; Zhang R; Yang X; Schmitt D; Fu X; Shao M; Brennan DM; Ellis SG; Brennan ML; Allayee H; Lusis AJ; Hazen SL
JAMA; 2008 Mar; 299(11):1265-76. PubMed ID: 18349088
[TBL] [Abstract][Full Text] [Related]
18. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease.
Asleh R; Marsh S; Shilkrut M; Binah O; Guetta J; Lejbkowicz F; Enav B; Shehadeh N; Kanter Y; Lache O; Cohen O; Levy NS; Levy AP
Circ Res; 2003 Jun; 92(11):1193-200. PubMed ID: 12750308
[TBL] [Abstract][Full Text] [Related]
19. Hypothesis--haptoglobin genotype and diabetic nephropathy.
Nakhoul FM; Miller-Lotan R; Awaad H; Asleh R; Levy AP
Nat Clin Pract Nephrol; 2007 Jun; 3(6):339-44. PubMed ID: 17525716
[TBL] [Abstract][Full Text] [Related]
20. Vascular compliance in diabetes.
Winer N; Sowers JR
Curr Diab Rep; 2003 Jun; 3(3):230-4. PubMed ID: 12762971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
